HES1 and T-cell acute lymphoblastic leukemia: In vivo studies have confirmed that the IDH1-R132H mutation upregulates Hes1 expression and downregulates PTEN expression by activating the Notch1 pathway, thereby activating the PI3K/AKT pathway and promoting malignant behavior in T-cell acute lymphoblastic leukemia (T-ALL) cells (177).